Welcome to the Virtual Tour for Referring Pulmonologist & HCPs

Breakthrough Technology for Severe Emphysema

Helping Patients Breathe Easier, Do More, and Enjoy Life

The Zephyr^® Valve delivers durable clinical benefits — without surgery and its associated risks.^1-5

Patients experience:^1-5

Improved health status
Improved lung function
Increased exercise capacity
Reduced breathlessness or dyspnea
Reduced gas trapping
Improved quality of life

Pulmonologist Perspective:
How Zephyr Valves Work

Zephyr Valve Patient Benefits

How It Works

See how the Zephyr Valve treatment is performed as a minimally invasive lung volume reduction procedure to reduce hyperinflation and gas trapping in patients with severe emphysema. The Zephyr Valve is the first endobronchial valve to receive approval from the FDA for patients with either heterogenous or homogeneous emphysema.

Patient Selection for Endobronchial Valves

Key Patient Selection Criteria

Confirmed diagnosis of COPD
Non-smoking or willing to quit smoking
FEV₁≤50% predicted
Breathless despite optimal medical management (mMRC≥2)

Physician Education & Case Support for BLVR

Making a Referral:

Patients who might benefit from Zephyr Valve therapy include

Patients who are not responding to optimal medical management
Patients who prefer additional treatment options

Once Referred an Interventional Pulmonologist Will Confirm

Diagnosis of severe emphysema
Presence of hyperinflation (RV≥175% predicted)
Confirmation the target lobe has little to no collateral ventilation

Make a US Referral

Make an OUS Referral

Clinical Evidence

4 RCTs published using Zephyr Valve and Chartis^® to preselect patients^1-5
Published in the New England Journal of Medicine, The Lancet, and The American Journal of Respiratory and Critical Care Medicine^1-5,16

Statistically significant and clinically meaningful improvements compared to standard of care in multiple trials^1-4
Treatment success seen in a broad range of primary and secondary endpoints^1-5

Consistent Clinical Findings Across Four Randomized Controlled Trials

RCT	Design	Sample size & follow-up period	Procedural Success (TLVR%)	Difference Zephyr Valve vs. Control Groups (ITT)
RCT	Design	Sample size & follow-up period	Procedural Success (TLVR%)	Lung function (fev₁%) MCID = 10%-15%	Excercise capacity (6mwd) MCID = 26 m	quality of life (sgrq) MCID = -4 pts
LIBERATE¹	2:1 Randomization Heterogeneous only Multicenter	n=190 12 months	84%	18.0% p<0.001	39 m p=0.002	-7.1 pts p=0.004
TRANSFORM²	2:1 Randomization Heterogeneous only Multicenter	n=97 6 months	90%	29.3% p<0.001	79 m p<0.001	-6.5 pts p=0.031
IMPACT³	1:1 Randomization Homogeneous only Multicenter	n=93 6 months*	89%	16.3% p<0.001	28 m p=0.016	-7.5 pts p<0.001
STELVIO^4,5	1:1 Randomization Heterogeneous & Homogeneous Single Center	n=68 6 months	88%	17.8% p=0.001	74 m p<0.001	-14.7 pts** p<0.001

*Data on file at PMX (not in publication)

**Completed cases, all other values listed are ITT population

T Difference between valve and control groups

Pulmonx-Zephyr-Clinical-Study-Summary-Table

*Completed cases, all other values listed are ITT population

Featured Patient Stories

Earl’s Story

Maryland

Life Renewed: Maryland’s 1st Zephyr Valve Lung Implant Patient Shares His Story.

Charlie’s Story

Age at Treatment: 68
Fairfax, Virginia

My story about this procedure tells people what life can be even with COPD. It really brought me back. I am a walking Christmas present.

Zephyr-Case-Study-Patient-Story-Florence

Flo’s Story

Age at Treatment: 63
Texas City, TX

I feel strongly that part of my new path in life is to help spread the word about the Zephyr Valves so other sufferers can learn about this option and have hope.

View All Stories

LIBERATE¹ Primary & Secondary Endpoints

Primary Endpoint Responder Analysis

Percent of Subjects with FEV₁ Change of ≥15%

LIBERATE - Percent of Subjects with FEV1 Change of ≥15% at 12 Months | amCharts

Secondary Endpoints

Change in St. George’s Resp Questionnaire

LIBERATE - SGRQ - Line | amCharts

Change in FEV₁

LIBERATE - FEV1 - Line | amCharts

Change in 6MWD

LIBERATE - 6MWD - Line | amCharts

Zephyr Valve Procedure

Complications of the Zephyr Endobronchial Valve Treatment include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

Chat with Us

I am a...*
Hospital/Institution
Name*
First Last
Email*
Area for comment
*
I agree to my personal data being processed in accordance with Pulmonx’s Privacy Policy.*
CAPTCHA
Comments
This field is for validation purposes and should be left unchanged.